CLEVELAND, Nov. 13 OH-CRi-CleveClin-awd
CLEVELAND, Nov. 13 /PRNewswire/ -- Cambridge Research & Instrumentation,
Inc. (CRi) announced today that the technology of multispectral imaging was
ranked as a Top Ten Medical Innovation at Cleveland Clinic's 6th Annual
Medical Innovations Summit.
(Photo: http://www.newscom.com/cgi-bin/prnh/20081113/NETH122 )
During the recognition presentation, Dr. Jennifer Hunt, head of surgical
pathology at the Cleveland Clinic stated, "When we're talking about tumors,
we're talking about what information can we gain about that tumor to guide and
direct therapy, prognosis, diagnostics. We believe this technology to be a
game changer. It will take personalized medicine to an entirely new level.
This is not a step, but a leap. Being able to analyze multiple markers in a
single cell to understand the behavior of actual signaling pathways will
significantly aid in disease diagnosis and therapy development." Dr. Hunt went
on to add, "I expect that this technology will be rapidly adopted across the
field of pathology."
The list of devices and technologies was selected by a panel of physicians
and scientists affiliated with the Cleveland Clinic, and was unveiled during
the annual Medical Innovation Summit this week.
"We are honored and grateful that this technology was recognized by the
Clinic," says George Abe, CEO of CRi. "We are dedicated to developing
comprehensive solutions that will help produce breakthroughs in biomedical
research and medical care."
As biological imaging becomes more about studying complex systems rather
than single events, CRi's Nuance system allows users to monitor more than one
event or target at a time. The system produces clear and accurate unmixed
images from a multi-label tissue section, whether the tissue is labeled for
cellular, nuclear, or membrane markers that overlap spatially or spectrally.
"Our Nuance technology is like enabling a colorblind person to see color
for the first time," adds Clifford Hoyt, Chief Technology Officer of CRi.
"Among other things, it can be used by both pre-clinical and clinical research
scientists to reveal new data to expedite targeted therapies, and by
physicians for personalized treatment."
Four major criteria served as the basis for qualifying and selecting
Cleveland Clinic's Top 10 Medical Innovations. To receive consideration, a
nominated innovation was required to: have significant potential for short-
term clinical impact, have a high probability of success, be on the market or
close to being introduced, and have sufficient data available to support its
nomination.
Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based
biomedical imaging company providing innovative optical imaging solutions for
more than 20 years. CRi's multidisciplinary team is dedicated to providing
comprehensive solutions that enable customers to produce breakthroughs in
research and medical care. CRi technology helps extract new disease-specific
information from biological and clinical samples in the physiological,
morphological, and biochemical context of intact tissues and organisms.
With over 80 patents pending and issued, CRi's award-winning innovations
are being utilized around the world in a wide range of settings, ranging from
academic researcher to pharmaceutical drug development to clinical medicine.
CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art
manufacturing facility and is able to rapidly design and manufacture system-
level solutions for a variety of growing market applications.
Visit http://www.cri-inc.com/nuance to find out more about the Nuance
system.
For more information visit our website at www.cri-inc.com or contact:
Ross Nakatsuji
CRi Marketing/Sales Group Leader
35-B Cabot Road, Woburn, MA 01801 USA
(P) 1-781-935-9099, extension 177, (C) 1-781-405-4000,
(E) rnakatsuji@cri-inc.com
SOURCE Cambridge Research & Instrumentation, Inc.
